Pulmonary toxicity induced by carfilzomib: a case report and review of the literature
- Open Access
- 14-10-2025
- Adverse Effects of Cancer Therapy
- Case report
Published in:
- Authors
- Mateusz Ziarkiewicz
- Aleksandra Zacny
- Grzegorz Basak
- Laretta Grabowska-Derlatka
- Published in
- Journal of Medical Case Reports | Issue 1/2025
Abstract
Background
Carfilzomib (Kyprolis™) is a second-generation proteasome inhibitor registered for the management of relapsed or refractory multiple myeloma. Drug safety profile includes hypertension, heart failure, and acute kidney failure. There are only scarce data on carfilzomib pulmonary toxicity.
Case description
In this report, we present a case of a Caucasian man in his 50s diagnosed with multiple myeloma and treated with daratumumab–carfilzomib–dexamethasone as second-line therapy. After 5 months of treatment, the patient developed noninfectious interstitial pneumonitis with respiratory failure. After a thorough differential diagnosis, we identified the patient’s symptoms as a direct result of drug administration. Carfilzomib withdrawal alone led to clinical and radiologic improvement, whereas reintroducing the therapy worsened the condition. Daratumumab as monotherapy was continued without adverse events. The precise cause of carfilzomib pulmonary toxicity remains unknown.
Conclusion
Given the rarity of the reported syndrome, our case highlights the need to monitor pulmonary function on carfilzomib treatment, as well as the possibility of symptom cessation on early drug withdrawal without additional interventions.
Advertisement
- Title
- Pulmonary toxicity induced by carfilzomib: a case report and review of the literature
- Authors
-
Mateusz Ziarkiewicz
Aleksandra Zacny
Grzegorz Basak
Laretta Grabowska-Derlatka
- Publication date
- 14-10-2025
- Publisher
- BioMed Central
- Keywords
-
Adverse Effects of Cancer Therapy
Multiple Myeloma
Pneumonitis
Interstitial Lung Diseases
Pulmonary Emergencies
Hematologic Cancer - Published in
-
Journal of Medical Case Reports / Issue 1/2025
Electronic ISSN: 1752-1947 - DOI
- https://doi.org/10.1186/s13256-025-05564-w
This content is only visible if you are logged in and have the appropriate permissions.
